$2.070
+0.041 (+1.97%)Zum Schluss
SERA-News
SERA-Events
Sera Prognostics Appoints Scott Gleason as CFO
Sera Prognostics (SERA) announced that Scott Gleason has been appointed CFO, effective August 31. Most recently, he served as VP of investor relations and treasury at Neogen Corporation (NEOG). Austin Aerts, who has served as CFO since June 2023, will transition to an advisory capacity focused on strategic initiatives and ensuring continuity.
Company Reports Q2 Revenue of $30K, Below Expectations
Reports Q2 revenue $30K, consensus $50K. "During the second quarter, we continued to build momentum across the key drivers of long-term adoption, including payer engagement, policy advancement, clinical evidence generation, and organizational strength," said CEO Zhenya Lindgardt. "The launch of our fourth partnership program, progress in payer engagement, the new Illinois Medicaid coverage law, the publication of compelling PRIME data in first-time mothers, and growing recognition from the maternal-fetal medicine community reinforce our belief that precision, biology-driven pregnancy care can improve outcomes for mothers and babies while creating meaningful value for healthcare systems. While we remain in the early stages of market development, we have been encouraged by the steady month-to-month increase in testing volume following publication of the PRIME study, which we believe reflects growing provider awareness and adoption."
Sera Prognostics Joins $10.4M ARPA-H Research Program
Sera Prognostics (SERA) announced its participation in a multi-institutional research program that was awarded up to $10.4M by the Advanced Research Projects Agency for Health, or ARPA-H, to develop a novel point-of-care diagnostic test designed to improve the safety of labor and delivery. The award, part of ARPA-H's Making Obstetrics Care Smart program, supports a collaboration led by researchers at the University of California San Diego alongside Sera Prognostics and Allegro MicroSystems (ALGM). The program aims to develop new technologies that enable more precise, data-driven decision-making during childbirth. The research team is working to develop a diagnostic approach that can assess the risk of low fetal oxygen levels from a small maternal blood sample. The program will explore the integration of identified biomarkers into a rapid, point-of-care testing platform capable of delivering results from a small maternal blood sample.
Company Reports Q1 Revenue of $14K
Reports Q1 revenue $14K, consensus $66.67K. "In Q1, our primary focus was building awareness with clinicians and the broader stakeholder community as we continue the evolution from clinical stage to a commercial driven organization," said Zhenya Lindgardt, CEO. "We made meaningful progress translating our expanding clinical foundation into commercial readiness, supported by growing peer reviewed validation in Europe, increasing clinician engagement, expanded education and access through the launch of our third partnership program, and active discussions with 13 payers across 15 states. Our strong presence at SMFM and ACOG and continued progress toward CE marking underscore our focus on scaling in high-value markets and driving adoption of the PreTRM test." "During the quarter, we advanced into the next phase of our evolution as a commercial organization through a comprehensive business review. As discussed in prior quarters, we redirected investment from clinical spend toward reimbursement driven commercialization while maintaining a sustainable cost structure," said Austin Aerts, CFO. "These actions extended our cash runway by approximately one year, through 2029, providing the financial flexibility to fund the company through key adoption and commercial milestones."
Sera Reports Q4 Revenue of $10K, Down 58.33% YoY
Reports Q4 revenue $10K vs. $24K last year. In February 2025, Sera completed an underwritten public offering of common stock and pre-funded warrants extending cash runway through 2028. "2025 marked a pivotal year for Sera as we moved from clinical validation to commercial execution," said Zhenya Lindgardt, CEO. "The publication of the landmark PRIME Study delivered strong, peer-reviewed evidence that the PreTRM Test improves outcomes and reduces costs, creating a compelling value proposition for payers. During the year we expanded engagement across our target states, advanced active discussions with both commercial and Medicaid payers, and invested deliberately in leadership, access and infrastructure to support us as we scale. With a strengthened balance sheet, extending our runway through 2028, we enter 2026 focused on converting this foundation into broader adoption, payer coverage, and measurable impact for the families we serve."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.